Previous 10 | Next 10 |
home / stock / rhhbf / rhhbf news
2023-09-02 14:00:00 ET More on pharma companies Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad? Novo Nordisk: Super Focused Pharma Company For The Long Run Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rati...
2023-08-29 13:45:03 ET Summary Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as ...
2023-08-29 07:14:31 ET More on Halozyme, Roche, etc. Halozyme Therapeutics, Inc. ( HALO ) Q2 2023 Earnings Call Transcript Roche: FX Drug But Positive Outlook Roche Holding AG ( OTCQX:RHHBY ) Q2 2023 Earnings Call Transcript Halozyme: Inflection Point...
2023-08-23 14:46:51 ET Summary 14-week data from the phase 2 LUNA study, using Ixo-vec for the treatment of patients with wet age-related macular degeneration, expected in late Q3 of 2023. Preliminary safety and efficacy data from phase 2 LUNA study, using Ixo-vec for the treatmen...
2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...
2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...
2023-08-07 11:25:39 ET More on Poseida Poseida Therapeutics: Pioneering Cell And Gene Therapies Spark Excitement And Caution Poseida gains on FDA nod to start trials for CAR-T therapy Poseida stock falls ~8% postmarket after founder, executive chairman to step down ...
2023-08-06 07:45:00 ET Summary Fiduciary Management, Inc. is an independent money management firm. FMI’s equity investing strategies apply a value discipline, with a focused approach firmly rooted in fundamental research. Global equity markets have continued to advance desp...
2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...
2023-08-03 08:52:55 ET More on Aravive Aravive: Very Small Company With Late Stage Trial In Ovarian Cancer Aravive stock pops on FDA orphan drug status for batiraxcept to treat pancreatic cancer Aravive gains on FDA Fast Track status for lead program Aravive ...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...